Mexico Cancer Immunotherapy Market Size & Outlook
Mexico cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Mexico cancer immunotherapy market highlights
- The Mexico cancer immunotherapy market generated a revenue of USD 947.9 million in 2023 and is expected to reach USD 1,730.5 million by 2030.
- The Mexico market is expected to grow at a CAGR of 9% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 947.9 million |
| Market revenue in 2030 | USD 1,730.5 million |
| Growth rate | 9% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Mexico accounted for 0.8% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Argentina is the fastest growing regional market in Latin America and is projected to reach USD 1,016.6 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 66.43% in 2023. Horizon Databook has segmented the Mexico cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Several emerging and alternative cancer treatments pose a threat to the immunotherapeutic drugs in Mexico, such as laser cancer therapy, hyperthermia, DMSO potential therapy, insulation potential therapy, enzymatic cancer therapy, and oxygen therapy.
However, there is a lack of data regarding the epidemiology of cancer in Mexico as it does not have a population-based cancer registry. According to an article published in the JCO Global Oncology, the incidence of cancer in the Central and South American region is estimated to increase to 1.7 million by 2030.
Moreover, various government and nongovernment organizations are striving to create awareness of various types of cancers in Mexico. This, in turn, is expected to drive the market over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico cancer immunotherapy market size, by product, 2018-2030 (US$M)
Mexico Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
